Endothelium-specific gene and stem cell-based therapy for erectile dysfunction.
- Author:
Travis D STRONG
1
;
Milena A GEBSKA
;
Arthur L BURNETT
;
Hunter C CHAMPION
;
Trinity J BIVALACQUA
Author Information
1. Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
- Publication Type:Journal Article
- MeSH:
Animals;
Cell Differentiation;
Endothelial Cells;
Endothelium, Vascular;
Erectile Dysfunction;
therapy;
Genetic Therapy;
Humans;
Male;
Multipotent Stem Cells;
transplantation;
Nitric Oxide Synthase Type III;
genetics;
Stem Cell Transplantation;
Superoxide Dismutase;
genetics;
Vascular Endothelial Growth Factor A;
genetics
- From:
Asian Journal of Andrology
2008;10(1):14-22
- CountryChina
- Language:English
-
Abstract:
Erectile dysfunction (ED) commonly results from endothelial dysfunction of the systemic vasculature. Although phosphodiesterase type 5 (PDE-5) inhibitors are effective at treating most cases of ED, they must be taken routinely and are ineffectual for a meaningful number of men. In recent years gene and stem cell-based therapies targeted at the penile endothelium have been gaining momentum in preclinical studies. These early studies reveal that gene and stem cell-based therapies may be both enduring and efficacious, and may eventually lead to a cure for ED. The following review will highlight our current understanding of endothelial-specific gene and stem cell-based therapies performed to date in a number of experimental animal models.
